1-(2-hydroxypropyl)cyclopropanol | 321916-67-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(2-hydroxypropyl)cyclopropanol
• 英文别名: 1-(2-hydroxypropyl)cyclopropan-1-ol
• CAS: 321916-67-0
• 化学式: C₆H₁₂O₂
• 分子量: 116.16
• InChiKey: XAEAJKZLMUCMLK-UHFFFAOYSA-N

物化性质

• 沸点：
  231.0±8.0 °C(Predicted)
• 密度：
  1.154±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  40.5
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(2-hydroxypropyl)cyclopropanol 在 sodium azide 、 氯化铵 、 三乙胺 、 三苯基膦 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 生成 1-(2-aminopropyl)cyclopropyl alcohol
  参考文献：
  名称：

  The Kulinkovich Reaction on Lactones. A Convenient Approach to Functionalized Cyclopropanols

  摘要：

  DOI：

  10.1021/jo0011944
• 作为产物：
  描述：

  1-[2-(tetrahydro-2H-pyran-2-yloxy)propyl]cyclopropanol 在 4-甲基苯磺酸吡啶 作用下， 以 甲醇 为溶剂， 反应 0.5h， 以83%的产率得到1-(2-hydroxypropyl)cyclopropanol
  参考文献：
  名称：

  The First Synthesis of Spirocyclic Sulfates from Tertiary Cyclopropanols and Their Reaction with Normant Homocuprates

  摘要：

  DOI：

  10.1055/s-0034-1378343

文献信息

• CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20140088117A1

  公开（公告）日：2014-03-27

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I的环醚吡唑-4-基-杂环基-羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2为环醚，X为噻唑基、吡啶基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I化合物进行体外、体内和体内诊断、预防或治疗哺乳动物细胞中的这类疾病或相关病理条件的方法。
• [EN] OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS OXÉPAN-2-YL-PYRAZOL-4-YL-HÉTÉROCYCLYLE-CARBOXAMIDE ET LEURS MÉTHODES D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2015140189A1

  公开（公告）日：2015-09-24

  Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  氧杂环戊烷-2-基吡唑-4-基杂环基甲酰胺化合物的化学式I，包括立体异构体、几何异构体、互变异构体和其药用可接受的盐，其中X为噻唑基、吡啶基、吡啶基或嘧啶基，用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用化合物I的方法，用于体外、原位和体内诊断、预防或治疗哺乳动物细胞中的这类疾病，或相关的病理条件。
• Efficient Synthesis of β-CF₃/SCF₃-Substituted Carbonyls via Copper-Catalyzed Electrophilic Ring-Opening Cross-Coupling of Cyclopropanols
  作者：Yong Li、Zhishi Ye、Tabitha M. Bellman、Teng Chi、Mingji Dai

  DOI：10.1021/acs.orglett.5b00782

  日期：2015.5.1

  The first copper-catalyzed ring-opening electrophilic trifluoromethylation and trifluoromethylthiolation of cyclopropanols to form Csp3–CF3 and Csp3–SCF3 bonds have been realized. These transformations are efficient for the synthesis of β-CF3- and β-SCF3-substituted carbonyl compounds that are otherwise challenging to access. The reaction conditions are mild and tolerate a wide range of functional

  已经实现了第一个铜催化的环丙醇开环亲电三氟甲基化和三氟甲基硫醇化形成C sp3 -CF 3和C sp3 -SCF 3键。这些转化对于合成β-CF 3 -和β-SCF 3 -取代的羰基化合物是有效的，否则这些化合物很难获得。反应条件温和，可耐受多种官能团。还报道了用于 LY2409021 的简明合成，这是一种用于 2 型糖尿病临床试验的胰高血糖素受体拮抗剂。
• Cyclic Ether Pyrazol-4-YL-Heterocyclyl-Carboxamide Compounds And Methods Of Use
  申请人：Genentech, Inc.

  公开号：US20160213652A1

  公开（公告）日：2016-07-28

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R 2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基卡氧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，可用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。公开了使用公式I中的化合物进行哺乳动物细胞中的体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。
• Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
  申请人：Genentech, Inc.

  公开号：US09328106B2

  公开（公告）日：2016-05-03

  Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

  公式I中的环氧杂环基羧酰胺化合物，包括立体异构体、几何异构体、互变异构体和其药学上可接受的盐，其中R2是一个环氧杂环基，X是噻唑基、吡嗪基、吡啶基或嘧啶基，用于抑制Pim激酶，并用于治疗由Pim激酶介导的癌症等疾病。本文介绍了利用公式I中的化合物在哺乳动物细胞中进行体外、原位和体内诊断、预防或治疗此类疾病或相关病理条件的方法。